Grass pollen allergy vaccine tablet - ALK-Abello

Drug Profile

Grass pollen allergy vaccine tablet - ALK-Abello

Alternative Names: ALK Tablet; Grass AIT; Grass pollen allergy therapy - ALK-Abello; Grastek; Grazax; MK-7243; Phleum pratense pollen extract; SCH-697243

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ALK-Abello
  • Developer Abbott Laboratories; ALK-Abello; Merck & Co; Seqirus
  • Class Allergens; Antiallergics; Plant allergy immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Seasonal allergic rhinitis
  • Phase III Allergic asthma

Most Recent Events

  • 07 Jul 2017 Launched for Seasonal allergic rhinitis in Australia (Sublingual)
  • 03 Jul 2017 Registered for Seasonal allergic rhinitis in Australia (Sublingual)
  • 31 Jan 2017 Merck terminates its licence for grass pollen allergy vaccine in North America (ALK-Abello Annual Report 2016; 9212363)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top